You need to be logged in to view this video

Actinium Pharmaceuticals, Inc.

Released on Thursday, October 7, 2021BIOTECH
Steve O'Loughlin will present Actinium's leadership in the targeted radiotherapy field and how it is the only company pursuing well-validated targets in hematology with late-stage clinical programs. You will learn how the company's Iomab-B and Actimab-A programs have yielded promising clinical data in the relapsed/refractory Acute Myeloid Leukemia (AML). Finally, Mr. O'Loughlin will cover the company's investments in R&D, driving continued innovation in developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.

Steve O'Loughlin
Actinium Pharmaceuticals, Inc., Chief Financial Officer

Trending Now


Filter By Category
Filter By Keywords
Loading...
Live Now

Accredited Investors Virtual Expo

August 9 - 11, 2022